State Board of Administration of Florida Retirement System bought a new stake in shares of EQRx, Inc. (NASDAQ:EQRX – Get Rating) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 37,000 shares of the company’s stock, valued at approximately $91,000.
Several other institutional investors also recently bought and sold shares of the stock. Handelsbanken Fonder AB bought a new position in EQRx during the fourth quarter valued at about $327,000. SG Americas Securities LLC grew its position in shares of EQRx by 357.5% in the fourth quarter. SG Americas Securities LLC now owns 135,252 shares of the company’s stock valued at $333,000 after purchasing an additional 105,689 shares during the last quarter. ProShare Advisors LLC grew its position in shares of EQRx by 199.0% in the fourth quarter. ProShare Advisors LLC now owns 66,263 shares of the company’s stock valued at $163,000 after purchasing an additional 44,102 shares during the last quarter. Beaumont Financial Advisors LLC acquired a new stake in shares of EQRx in the fourth quarter valued at about $1,799,000. Finally, Bank of New York Mellon Corp grew its position in shares of EQRx by 47.5% in the third quarter. Bank of New York Mellon Corp now owns 858,315 shares of the company’s stock valued at $4,248,000 after purchasing an additional 276,259 shares during the last quarter. 82.61% of the stock is currently owned by institutional investors.
EQRx Stock Performance
Shares of NASDAQ:EQRX opened at $1.85 on Wednesday. The company has a market cap of $901.62 million, a P/E ratio of -3.25 and a beta of 0.57. The stock’s 50-day moving average is $1.80 and its 200-day moving average is $2.40. EQRx, Inc. has a 52-week low of $1.58 and a 52-week high of $6.05.
EQRx Company Profile
EQRx, Inc, a pharmaceutical company, engages in developing medicines primarily for the treatment of oncology and immune-inflammatory diseases in the United States. The company's pre-registrational programs in Phase III clinical trial include Aumolertinib, an epidermal growth factor receptor (EGFR) inhibitor for the treatment of patients with EGFR-mutated non-small cell lung cancer (NSCLC); and Sugemalimab, an anti-programmed death-ligand 1 antibody for the treatment of Stage III and Stage IV NSCLC.
- Get a free copy of the StockNews.com research report on EQRx (EQRX)
- Airline ETFs: What They Are and How to Invest
- Williams-Sonoma Is The Retail Value Play, Here’s Why
- Ladder Corporation: Climbing Higher And Paying 9% Yield
- Microbot Medical spikes 150% on its Endovascular Surgical Robot
- PetMed Express: Charts Say This Could Be The Bottom
Want to see what other hedge funds are holding EQRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for EQRx, Inc. (NASDAQ:EQRX – Get Rating).
Receive News & Ratings for EQRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EQRx and related companies with MarketBeat.com's FREE daily email newsletter.